Epigenetic diagnostics of cancer--the application of DNA methylation markers.
In recent years it has become apparent that epigenetic events are potentially equally responsible for cancer initiation and progression as genetic abnormalities. DNA methylation is the main epigenetic modification in humans. Two DNA methylation lesions coexist in human neoplasms: hypermethylation of promoter regions of specific genes within a context of genomic hypomethylation. Aberrant methylation is found at early stages of carcinogenesis and distinct types of cancer exhibit specific patterns of methylation changes. Tumor specific DNA is readily obtainable from different clinical samples and methylation status analysis often permits sensitive disease detection. Methylation markers may also serve for prognostic and predictive purposes as they often reflect the metastatic potential and sensitivity to therapy. As current findings show a great potential of recently characterised methylation markers, more studies in the field are needed in the future. Large clinical studies of newly developed markers are especially needed. The review describes the diagnostic potential of DNA methylation markers.
Paluszczak
Jaroslaw
J
Department of Pharmaceutical Biochemistry, Poznań University of Medical Sciences, Grunwaldzka 6, 60-780 Poznań, Poland.
Baer-Dubowska
Wanda
W
D014408:Biomarkers, Tumor / Q000032:analysis*; D019175:DNA Methylation; D044127:Epigenesis, Genetic; D005819:Genetic Markers; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy; D011401:Promoter Regions, Genetic
D014408:Biomarkers, Tumor; D005819:Genetic Markers